Category: ANTI BIOTICS
Product Description
Supacef® 750 mg Injection contains Cefuroxime Sodium, a second-generation cephalosporin antibiotic with broad-spectrum bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bacterial cell death.
Supacef® Injection is indicated for the treatment of moderate to severe bacterial infections and for surgical prophylaxis. It is stable against many β-lactamases, making it effective against numerous resistant pathogens commonly encountered in hospital and community settings.
Indications
Supacef® Injection is indicated for the treatment of susceptible infections, including:
- Lower respiratory tract infections, including pneumonia
- Upper respiratory tract infections, including sinusitis, tonsillitis, and otitis media
- Urinary tract infections
- Skin and soft tissue infections
- Bone and joint infections
- Septicaemia (bacteraemia)
- Meningitis caused by susceptible organisms
- Gonorrhoea
- Intra-abdominal infections
- Pelvic infections
- Surgical prophylaxis in orthopaedic, gastrointestinal, gynaecological, cardiovascular, thoracic, and urological procedures
Contraindications
Supacef® Injection is contraindicated in patients with:
- Known hypersensitivity to cefuroxime, other cephalosporins, or any component of the formulation.
- History of severe immediate hypersensitivity reactions (e.g., anaphylaxis) to penicillins or other β-lactam antibiotics.
Use with caution in patients with renal impairment, gastrointestinal disease (especially colitis), or a history of allergy to penicillins.
Dosage and Administration
Supacef® Injection may be administered by intravenous (IV) or intramuscular (IM) injection.
Adults
- 750 mg every 8 hours for most infections.
- Severe infections: 1.5 g every 8 hours, which may be increased to every 6 hours if necessary.
- Life-threatening infections may require up to 6 g/day in divided doses.
Children
- 30–100 mg/kg/day in 3–4 divided doses depending on the severity of infection.
Neonates
- 30–100 mg/kg/day in 2–3 divided doses.
Surgical Prophylaxis
- 1.5 g IV at induction of anaesthesia, with additional doses if required depending on the procedure.
Patients with Renal Impairment
- Dosage adjustment is required according to creatinine clearance.
Key Features
- Second-generation cephalosporin antibiotic
- Broad-spectrum bactericidal activity
- Effective against β-lactamase-producing organisms
- Suitable for IV and IM administration
- Excellent tissue and body fluid penetration
- Ideal for hospital and surgical use
- Proven efficacy in respiratory, urinary, skin, bone, and systemic infections